PTC Therapeutics Inc
F:BH3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
PTC Therapeutics Inc
F:BH3
|
US |
|
S
|
Swiss Re AG
OTC:SSREF
|
CH |
|
H
|
Hasbro Inc
DUS:HAS
|
US |
|
F
|
FibroGen Inc
SWB:1FG
|
US |
|
S
|
Schlumberger NV
SWB:SCL
|
US |
|
B
|
Bollore SE
XMUN:BOP
|
FR |
|
L
|
Lindsay Corp
F:LMF
|
US |
|
P
|
Patterson-UTI Energy Inc
XBER:PE1
|
US |
|
W
|
Waste Management Inc
F:UWS
|
US |
|
S
|
Sasol Ltd
XMUN:SAOA
|
ZA |
|
M
|
Meta Platforms Inc
XBER:FB2A
|
US |
Wall St Price Targets
BH3 Price Targets Summary
PTC Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BH3 is 74.49 EUR with a low forecast of 52.73 EUR and a high forecast of 104.57 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BH3's stock price target?
Price Target
74.49
EUR
According to Wall Street analysts, the average 1-year price target for BH3 is 74.49 EUR with a low forecast of 52.73 EUR and a high forecast of 104.57 EUR.
What is the Revenue forecast for PTC Therapeutics Inc?
Projected CAGR
-2%
Over the last 13 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 3 years is -2%.
What is the Gross Profit forecast for PTC Therapeutics Inc?
Projected CAGR
-5%
The compound annual growth rate for Gross Profit over the next 3 years is -5%.
What is the Operating Income forecast for PTC Therapeutics Inc?
Projected CAGR
-12%
The compound annual growth rate for Operating Income over the next 3 years is -12%.
What is the Pre-Tax Income forecast for PTC Therapeutics Inc?
Projected CAGR
-20%
The compound annual growth rate for Pre-Tax Income over the next 3 years is -20%.
What is the Net Income forecast for PTC Therapeutics Inc?
Projected CAGR
-20%
Over the last 13 years, the compound annual growth rate for Net Income has been 70%. The projected CAGR for the next 3 years is -20%.
